NCT05659186View on ClinicalTrials.gov

PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

December 30, 2022

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2025

Conditions

Thyroid Cancer

Interventions

DRUG

Tislelizumab

200mg IV Q3W

DRUG

Anlotinib

12mg PO QD

RADIATION

Radiotherapy

Multimodal Radiotherapy

Trial Locations (1)

610041

RECRUITING

Xingchen Peng, Chengdu

All Listed Sponsors

lead

West China Hospital

OTHER